SDIX to Report First Quarter 2010 Results on May 3, 2010

NEWARK, Del.--(BUSINESS WIRE)-- SDIX (Nasdaq:SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, expects to release its first quarter 2010 results at approximately 4 p.m. ET on Monday, May 3, 2010. The Company has scheduled an investor conference call for 4:30 p.m. ET on the same day.

The dial-in number for the live conference call will be 877-407-9210 (201-689-8049 outside the U.S.). A live webcast of the conference call will be available on the Company’s website, www.sdix.com, as well www.investorcalendar.com. For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on May 3, 2010 through 11:59 p.m. ET on May 17, 2010. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 349986.

About SDIX

SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has developed antibodies which advance its customers’ immuno-based work – reducing time, labor, and costs while increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis. For more information, visit www.sdix.com.

This news release may contain forward-looking statements reflecting SDI's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.



CONTACT:

SDIX Company Contact:
Glenn Frantz
Director, Communications
302-456-6789
[email protected]

KEYWORDS:   United States  North America  Delaware  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”